Função renal, hepática e cardíaca de cães hígidos sob terapia prolongada com celecoxibe

Abstract

The aim of this study was to evaluate the effects of long-term celecoxib therapy on renal, hepatic and cardiac profiles in healthy dogs. Twelve female were randomly assigned to 2 groups (G): Gcelecoxib: treated with celecoxib orally (5mg kg-1), every 12 hours, for 20 days (8.9±1.6 body weight); Gcontrol: received placebo orally, every 12 hours, for 20 days (9.8±1.8 body weight). Physical examination, renal function (urinalysis, urinary sodium and gamma-glutamyl transpeptidase -GGT), serum urea, creatinine, potassium and sodium, and endogenous creatinine clearance), clotting time (CT), cardiac biomarkers (creatine phosphokinase -CK and CK-MB) and liver function (aspartate aminotransferase -AST, alanine aminotransferase - ALT and albumin) were evaluated before, at 5, 10 and 20 days (T0, T5, T10 and T20) of treatment. The creatinine clearance values showed significant decrease at T20, in relation to T0 and T5 in the Gcelecoxib, and reduction in relation to Gcontrol at T10 and T20. The urinalysis, values of sodium, potassium, urea and creatinine serum and urinary GGT enzyme showed no difference through the study between moments or groups. There was a significant increase on CK values at T20 and on ALT values at T5, T10 and T20 in the Gcelecoxib, however with normal range values for dogs. Celecoxib revealed to be safe in relation to cardiac and hepatic profiles, even under prolonged therapy. However, it should be used judiciously during longterm therapy in dogs with renal dysfunction.